Liquid Biopsy Allows Monitoring of COVID-19 Damage to Cells, Tissues, and Organs
|
By LabMedica International staff writers Posted on 09 Feb 2021 |
|
Image: Transmission electron microscope image showing SARS-CoV-2, the virus that causes COVID-19. Virus particles are shown emerging from the surface of cells cultured in the laboratory (Photo courtesy of US NIAID, via Wikimedia Commons)
A recent study presented results that point to the utility of exploiting cell-free DNA as an analyte to monitor the damage caused to cells, tissues, and organs by COVID-19.
While COVID-19 primarily affects the lungs, evidence of systemic disease with multi-organ involvement has emerged. In order to better understand this phenomenon, investigators at Cornell University (Ithaca, NY, USA) and colleagues in the United States and Canada developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19.
For this study, the investigators employed a liquid biopsy method to conduct genome-wide methylation profiling of cell-free DNA in the blood plasma. They assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls.
The investigators reported finding evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. Furthermore, a high concentration of cell-free DNA in the blood was itself a strong prognostic marker for severe COVID-19 cases.
“A lot of what we have learned about the involvement of the virus with different organs is from invasive biopsies, postmortem biopsies,” said senior author Dr. Iwijn De Vlaminck, assistant professor of biomedical engineering at Cornell University. “But a liquid biopsy is potentially very useful as a biological measurement, a way to study what is going on in patients who have different types of symptoms, for example. It could be used to assess disease severity and help stratify patients in the care system. It could also potentially be a surrogate biomarker that you could include in randomized controlled trials of various anti-COVID therapies and anti-virals.”
The cell-free DNA study was published in the January 16, 2021, online edition of the journal Cell Med.
Related Links:
Cornell University
While COVID-19 primarily affects the lungs, evidence of systemic disease with multi-organ involvement has emerged. In order to better understand this phenomenon, investigators at Cornell University (Ithaca, NY, USA) and colleagues in the United States and Canada developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19.
For this study, the investigators employed a liquid biopsy method to conduct genome-wide methylation profiling of cell-free DNA in the blood plasma. They assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls.
The investigators reported finding evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. Furthermore, a high concentration of cell-free DNA in the blood was itself a strong prognostic marker for severe COVID-19 cases.
“A lot of what we have learned about the involvement of the virus with different organs is from invasive biopsies, postmortem biopsies,” said senior author Dr. Iwijn De Vlaminck, assistant professor of biomedical engineering at Cornell University. “But a liquid biopsy is potentially very useful as a biological measurement, a way to study what is going on in patients who have different types of symptoms, for example. It could be used to assess disease severity and help stratify patients in the care system. It could also potentially be a surrogate biomarker that you could include in randomized controlled trials of various anti-COVID therapies and anti-virals.”
The cell-free DNA study was published in the January 16, 2021, online edition of the journal Cell Med.
Related Links:
Cornell University
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Automated ELISA System
DS2 ELITE
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
Parkinson’s disease and dementia with Lewy bodies are frequently misdiagnosed, often being confused with Alzheimer’s disease because of overlapping symptoms. Objective diagnostics for these synucleinopathies... Read more
Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women globally and remains a leading cause of cancer-related deaths in more than 100 countries. Current diagnostic pathways rely on mammography,... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Microbiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
Pathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
Technology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more
